Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine
Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions
| Condition(s) | Lumbar Spinal Stenosis |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions |
| Who can participate | Inclusion Criteria: 1. Male or Female 2. Adult (≥18 yo) 3. Lumbar stenosis Exclusion Criteria: 1. Co-morbidities precluding surgery 2. ≤18 yo 3. Pregnant 4. Breastfeeding 5. Need for instrumented fusion 6. Prisoners 7. Intra-operative CSF leak (identified by gush of CSF) 8. Daily pre-operative opioid use of \> 25 morphine Eq/day 9. Previous lumbar surgery at indicated level |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Colorado, Denver |
| Locations | Aurora, Colorado, United States |
| Start date | 2019-09-08 |
| NCT ID | NCT04066296 |
| Official listing | https://clinicaltrials.gov/study/NCT04066296 |